secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2026-05-14T20:09:02+00:00
Accession:  0001437749-26-017049
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell Q1 2026 net income $1.9M, product sales up 28.4% to $10.4M
-------------------------------------------------------------------

- Net income $1.9M ($0.21/share) vs $1.4M ($0.16/share) in Q1 2025.
- Product sales $10.4M, up 28.4% YoY; gross margin 45.0% vs 41.6%.
- Cash position $6.8M at Mar 31, 2026, up from $3.8M; generated $3.4M free cash flow in Q1.
- Settled all disputes with former contract manufacturer for net $2M payment to ImmuCell, to fund capacity expansion.
- Manufacturing output increased to >450K units/month from ~380K in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000143774926017049/0001437749-26-017049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000143774926017049/iccc20260512_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-017049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer